SELLAS Life Sciences Group (SLS) Competitors $1.66 +0.01 (+0.61%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$1.72 +0.06 (+3.31%) As of 06/13/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SLS vs. SION, CDXC, XNCR, ORIC, GHRS, TSHA, KROS, BCYC, IOVA, and UPBShould you be buying SELLAS Life Sciences Group stock or one of its competitors? The main competitors of SELLAS Life Sciences Group include Sionna Therapeutics (SION), ChromaDex (CDXC), Xencor (XNCR), ORIC Pharmaceuticals (ORIC), GH Research (GHRS), Taysha Gene Therapies (TSHA), Keros Therapeutics (KROS), Bicycle Therapeutics (BCYC), Iovance Biotherapeutics (IOVA), and Upstream Bio (UPB). These companies are all part of the "pharmaceutical products" industry. SELLAS Life Sciences Group vs. Its Competitors Sionna Therapeutics ChromaDex Xencor ORIC Pharmaceuticals GH Research Taysha Gene Therapies Keros Therapeutics Bicycle Therapeutics Iovance Biotherapeutics Upstream Bio SELLAS Life Sciences Group (NASDAQ:SLS) and Sionna Therapeutics (NASDAQ:SION) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation. Do insiders and institutionals hold more shares of SLS or SION? 17.4% of SELLAS Life Sciences Group shares are owned by institutional investors. 1.4% of SELLAS Life Sciences Group shares are owned by company insiders. Comparatively, 3.9% of Sionna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts recommend SLS or SION? Sionna Therapeutics has a consensus target price of $38.50, suggesting a potential upside of 135.04%. Given Sionna Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sionna Therapeutics is more favorable than SELLAS Life Sciences Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SELLAS Life Sciences Group 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Sionna Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor SLS or SION? In the previous week, SELLAS Life Sciences Group had 1 more articles in the media than Sionna Therapeutics. MarketBeat recorded 5 mentions for SELLAS Life Sciences Group and 4 mentions for Sionna Therapeutics. SELLAS Life Sciences Group's average media sentiment score of 1.14 beat Sionna Therapeutics' score of 0.88 indicating that SELLAS Life Sciences Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SELLAS Life Sciences Group 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sionna Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is SLS or SION more profitable? Sionna Therapeutics' return on equity of 0.00% beat SELLAS Life Sciences Group's return on equity.Company Net Margins Return on Equity Return on Assets SELLAS Life Sciences GroupN/A -629.46% -178.65% Sionna Therapeutics N/A N/A N/A Which has higher valuation and earnings, SLS or SION? Sionna Therapeutics has lower revenue, but higher earnings than SELLAS Life Sciences Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSELLAS Life Sciences Group$1M165.63-$37.34M-$0.38-4.37Sionna TherapeuticsN/AN/AN/AN/AN/A Does the MarketBeat Community favor SLS or SION? SELLAS Life Sciences Group received 7 more outperform votes than Sionna Therapeutics when rated by MarketBeat users. However, 75.00% of users gave Sionna Therapeutics an outperform vote while only 55.56% of users gave SELLAS Life Sciences Group an outperform vote. CompanyUnderperformOutperformSELLAS Life Sciences GroupOutperform Votes1055.56% Underperform Votes844.44% Sionna TherapeuticsOutperform Votes375.00% Underperform Votes125.00% SummarySionna Therapeutics beats SELLAS Life Sciences Group on 7 of the 12 factors compared between the two stocks. Get SELLAS Life Sciences Group News Delivered to You Automatically Sign up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLS vs. The Competition Export to ExcelMetricSELLAS Life Sciences GroupPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$165.63M$6.88B$5.57B$8.50BDividend YieldN/A2.48%5.27%4.17%P/E Ratio-2.418.4626.7519.66Price / Sales165.63261.91403.98152.07Price / CashN/A65.8538.2534.64Price / Book-6.646.526.964.59Net Income-$37.34M$143.26M$3.23B$248.23M7 Day Performance3.11%-0.21%-1.22%-1.07%1 Month Performance3.75%10.62%6.34%2.59%1 Year Performance10.67%3.63%33.05%13.50% SELLAS Life Sciences Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLSSELLAS Life Sciences Group0.5092 of 5 stars$1.66+0.6%N/A+10.7%$165.63M$1M-2.4110News CoveragePositive NewsShort Interest ↑SIONSionna TherapeuticsN/A$13.97+2.0%$38.50+175.6%N/A$616.41MN/A0.0035CDXCChromaDex2.5953 of 5 starsN/A$9.03+∞N/A$611.50M$99.60M787.29120XNCRXencor4.1174 of 5 stars$8.58+7.3%$29.50+243.8%-55.3%$610.65M$127.23M-2.68280Positive NewsGap UpORICORIC Pharmaceuticals3.8411 of 5 stars$8.47+3.7%$19.17+126.3%+28.6%$602.12MN/A-4.6580News CoveragePositive NewsAnalyst RevisionHigh Trading VolumeGHRSGH Research1.7685 of 5 stars$11.56-3.9%$30.43+163.2%+6.4%$601.44MN/A-14.6310News CoverageAnalyst RevisionTSHATaysha Gene Therapies3.7982 of 5 stars$2.79+3.0%$7.29+161.1%-36.0%$598.91M$7.22M4.43180Analyst ForecastAnalyst RevisionGap DownKROSKeros Therapeutics3.6134 of 5 stars$14.66+3.6%$37.00+152.4%-72.5%$595.42M$214.71M-2.81100Analyst DowngradeBCYCBicycle Therapeutics3.3486 of 5 stars$8.55+4.0%$25.00+192.4%-63.8%$592.12M$25.72M-2.60240News CoverageAnalyst RevisionGap DownIOVAIovance Biotherapeutics4.6355 of 5 stars$1.76+0.6%$13.30+655.7%-72.5%$587.72M$212.68M-1.18500Trending NewsGap DownUPBUpstream Bio1.9118 of 5 stars$10.66+15.5%$56.50+430.0%N/A$573.44M$2.30M0.0038Gap DownHigh Trading Volume Related Companies and Tools Related Companies Sionna Therapeutics Alternatives ChromaDex Alternatives Xencor Alternatives ORIC Pharmaceuticals Alternatives GH Research Alternatives Taysha Gene Therapies Alternatives Keros Therapeutics Alternatives Bicycle Therapeutics Alternatives Iovance Biotherapeutics Alternatives Upstream Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLS) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SELLAS Life Sciences Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SELLAS Life Sciences Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SLS Stock Free SLS Stock Alerts